References
- Lin X, Liu J, Hu SF, et al. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer. Cancer Manag Res. 2019;11:2203–2214. doi:10.2147/CMAR.S192949.31114314
- Xie JY, Chen PC, Zhang JL, et al. The prognostic significance of DAPK1 in bladder cancer. PLoS One. 2017;12(4):e0175290. doi:10.1371/journal.pone.0175290.28388658
- Shi-Peng G, Chun-Lin C, Huan W, et al. TMED2 promotes epithelial ovarian cancer growth. Oncotarget. 2017;8(55):94151–94165. doi:10.18632/oncotarget.21593.29212217
- Holliday DL, Spiers V. Choosing the right cell line for breast cancer research. Breast Cancer Research. 2011;13(4):215. doi:10.1186/bcr288921884641
- Tury S, Becette V, Assayag F, et al. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. Oncotarget. 2016;7(51):85124–85141. doi:10.18632/oncotarget.13200.27835884